JODAS HAS EVOLVED SIGNIFICANTLY, AS A GENERICS NEW GENERATION PHARMACEUTICAL COMPANY

  • 2006 – Founded the organization in India
  • 2006 – Started a subsidiary and regional office in Russia
  • 2007 – 3 molecules of anti-infectives commercialized in Russia
  • 2010 – 14 molecules of anti-infectives commercialized in Russia
  • 2010 – Launched Oncology products in Russia
  • 2011 – Conducted BE study for Temozolomide caps in Russia
  • 2012 – Achieved 38 SKUs commercialization in Russia
  • 2012 – Conducted BE study Gefitinib tabs in Russia
  • 2012 – Laid foundation for the green field Global facility at Hyderabad, India.
  • 2013 – Launched Cardiac critical care and Radio Contrast Media products
  • 2013 – Conducted BE study of Enoxaparin Inj in Russia
  • 2014 – Completed 43 BE studies in Russia
  • 2014 – Successfully marked our foot print in more than 50 cities in Russia
  • 2014 – Achieved significant market share with 7mn Injectables commercialized
  • 2014 – Achieved 68 Products registration in Russia
  • 2015 – Completed Phase –I (Cephalosporin’s unit) of our Global facility in Hyderabad, India.
  • 2016 – Completed Phase –II Oncology block for orals (Oncology orals) of our Global facility in Hyderabad, India.
  • 2017 – Completed Contrast media unit of our Global facility in Hyderabad, India.
  • 2018 – Completed Oncology sterile unit of our Global facility in Hyderabad, India.
  • 2018 – Received EUGMP certificate for Cephalosporin’s and Oncology orals.
  • 2018 – Completed unit for general injectables.